Skip to content

Earnings call

Tarsons Products Q1 FY27 earnings call

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Tarsons expects profit to remain relatively moderate in FY’27 as higher depreciation and interest costs are absorbed ahead of the full ramp-up of its new facilities. A large portion of the products at Tarsons’ Panchla facility have been commissioned, while a few select lines continued commissioning in Q1 FY’27; the number of machines and lines and supplier and engineering challenges delayed commissioning of the remaining lines by a few months. Tarsons consolidated revenue in Q1 FY’27 was Rs. 110 crores, growing by almost 21% Y-o-Y; standalone revenue was Rs. 86 crores, growing by 21% Y-o-Y and marking Tarsons’ highest-ever Q1 standalone revenue. Tarsons saw a meaningful demand revival and improvement across the end-to-end industries it serves, with a notable uptick in customer inquiries during Q1 FY’27. Tarsons’ gross debt was about INR 380 crores and net debt about INR 330-340 crores.

The numbers management gave

Results

  • Tarsons consolidated revenue in Q1 FY’27 was Rs. 110 crores, growing by almost 21% Y-o-Y; standalone revenue was Rs. 86 crores, growing by 21% Y-o-Y and marking Tarsons’ highest-ever Q1 standalone revenue.
    Show source
    Building on the momentum from the previous quarter, we delivered a healthy performance in Q1 FY’27 with consolidated revenue of Rs. 110 crores, growing by almost 21% Y-o-Y. Our standalone revenue also grew by 21% Y-o-Y and came to Rs. 86 crores, marking our highest ever Q1 standalone revenue.
  • Tarsons domestic sales grew 17% Y-o-Y in Q1 FY’27, supported by its distribution network, deeper customer engagement and improving demand conditions.
    Show source
    Our domestic sales grew 17% Y-o-Y, supported by the strength of our extensive distribution network, deeper customer engagement and improving demand conditions.
  • Tarsons’ Q1 FY’27 growth was driven predominantly by its existing product portfolio, with negligible contributions from incremental capacities and newly introduced product categories.
    Show source
    Importantly, this growth delivered in the quarter has been driven predominantly by our existing product portfolio, with negligible contributions coming from our incremental capacities and newly introduced product categories.
  • Tarsons’ export business from India grew 29% in the first quarter following disruption in previous quarters due to geopolitical tensions in West Asia and uncertainties related to U.S. tariffs.
    Show source
    Speaking of our overseas business, following the disruption witnessed in the previous quarters due to geopolitical tensions in West Asia and the uncertainties related to the U .S. tariffs, our export business from India saw a healthy recovery, growing 29% in the first quarter.
  • Tarsons’ German-based subsidiary revenue grew approximately 6% year-on-year in constant currency terms during Q1 FY’27.
    Show source
    During the quarter, our German-based subsidiary delivered a resilient performance, with revenue growing approximately 6% year-on-year in constant currency terms.
  • Tarsons’ margins moderated in Q1 FY’27 primarily due to the sharp escalation in raw material prices over recent months, with key input costs up 25% to 50%, putting pressure on gross margins.
    Show source
    Our key input costs have gone up anywhere in the range of 25% to 50%, putting pressure on gross margins.
Show 17 more statements

Results

  • Tarsons’ EBITDA in Q1 FY’27 was further impacted by operating costs associated with recently commissioned facilities.
    Show source
    EBITDA was further impacted by the operating costs associated with the recently commissioned facilities.
  • Tarsons’ Q1 FY’27 profit remained impacted by higher depreciation and interest costs following commissioning of its new CAPEX.
    Show source
    Profit for Quarter 1 remains impacted by higher depreciation and interest costs, followed by the commissioning of our new CAPEX.
  • Tarsons consolidated cash profit in Q1 FY’27 stood at INR 25.6 crores, growing 18% year-on-year.
    Show source
    This is reflected in the steady improvement in the cash profit, which has grown 18% year-on- year and stood at INR 25.6 crores on a consolidated basis.
  • Tarsons standalone revenue in Q1 FY’27 was INR 86.1 crores compared to INR 71.3 crores in Q1 FY’26, growing almost 21% year-on-year.
    Show source
    Revenue for Q1 FY’27 stood at INR 86.1 crores compared to INR 71.3 crores in Q1 FY’26, registering a growth of almost 21% on a year-on-year basis.
  • Tarsons exports grew almost 29% year-on-year in Q1 FY’27.
    Show source
    Exports have rebounded strongly this quarter, growing by almost 29% on a Y-o-Y basis.
  • Tarsons standalone gross margin in Q1 FY’27 stood at 67.1%, impacted by higher raw material costs arising from the spike in polymer prices.
    Show source
    Gross margin for the standalone business in Q1 FY’27 stood at 67.1%, impacted by higher raw material costs arising from the spike in polymer prices.
  • Tarsons standalone EBITDA in Q1 FY’27 stood at INR 24.2 crores.
    Show source
    EBITDA for Q1 FY’27 stood at INR 24.2 crores.
  • Tarsons’ EBITDA margin in Q1 FY’27 was impacted by lower gross margin and higher commissioning and operational expenses related to its new facilities.
    Show source
    EBITDA margin was impacted by the lower gross margin and the higher commissioning and operational expenses related to the new facilities.
  • Tarsons standalone cash profitability in Q1 FY’27 stood at INR 25.2 crores, growing 18% year-on-year.
    Show source
    Cash profitability for the quarter stood at INR 25.2 crores, showing a healthy growth of 18% on a Y-o-Y basis.
  • Tarsons consolidated revenue in Q1 FY’27 stood at INR 110.2 crores, growing 20.7% year-on-year.
    Show source
    Speaking about the consolidated performance, consolidated revenue for Q1 FY’27 stood at INR 110.2 crores, registering a strong growth of 20.7% Y-o-Y basis.
  • Tarsons consolidated EBITDA in Q1 FY’27 stood at INR 26 crores, with an EBITDA margin of 23.6%.
    Show source
    Consolidated EBITDA in Q1 FY’27 stood at INR 26 crores, with the EBITDA margin at 23.6%.
  • Most of Tarsons’ Panchla revenue in Q1 FY’27 came from existing products or capacity expansions moved to Panchla; the company did not have an exact contribution figure.
    Show source
    Aryan Sehgal: So, we don’t have an exact number in line, but most of the revenue contributed from Panchla in Quarter 1 are for existing products or capacity expansions which have moved into Panchla.
  • Tarsons’ Panchla revenue in Q1 FY’27 included bioprocess containers such as media bottles and roller bottles, but not cell culture consumables.
    Show source
    Aryan Sehgal: No, not from the cell culture consumables, but it has got contribution from the bioprocess containers and so on, which are the media bottles and roller bottles.
  • Tarsons’ standalone depreciation this year was INR 24.5 crores, including INR 14 crores from Panchla and INR 4 crores from Amta; Tarsons had INR 160 crores of capital work in progress that it believed would be capitalized and moved to the main capital asset segment in a subsequent quarter.
    Show source
    That includes a depreciation of INR 14 crores from Panchla and INR 4 crores from Amta and still we have INR 160 crores of capital work in progress, which we think that, that will be capitalized and moved to main capital asset segment in the subsequent quarter.
  • Tarsons’ profitability continues to be impacted by higher depreciation and interest expenses associated with its new CAPEX.
    Show source
    Profitability continues to be impacted by higher depreciation and interest expenses associated with the new CAPEX.
  • Tarsons attributed the decline in gross margin to higher input costs and raw-material purchase prices and an inability to pass the entire price increase on to customers.
    Show source
    The pure reason for gross margin going down is higher input costs and higher purchase price of raw materials and inability to pass on the entire price increase to customers.

Money and capital

  • Tarsons’ gross debt was about INR 380 crores and net debt about INR 330-340 crores.
    Show source
    The gross debt for the company is about to be INR 380 crores, and the net debt is about to be INR 330-340 crores, something like that.

What it expects ahead

What management expects

  • Tarsons expects profit to remain relatively moderate in FY’27 as higher depreciation and interest costs are absorbed ahead of the full ramp-up of its new facilities.
    Show source
    We expect the profit to remain relatively moderate in FY’27, as these costs are absorbed ahead of the full ramp-up of the new facilities.
  • Tarsons expects benefits from its capacity expansion to become increasingly visible from FY ’28 onwards as production ramps up and customer approvals and product adoption progress, supported by better fixed cost absorption and operating leverage.
    Show source
    Page 4 of 18 Tarsons Products Limited August 11, 2026 As the production ramps up, customer approvals and product adoption progress, we expect benefits of these investments to become increasingly visible from FY ’28 onwards, supported by better fixed cost absorption and operating leverage.
  • Tarsons believed full-year depreciation would be approximately INR 105 crores to INR 110 crores and that this would be its peak year for depreciation.
    Show source
    So, we believe that in the full year, the depreciation will be in the range of approximately INR 105 crores to INR 110 crores.
  • Tarsons can assume net debt will reduce by INR 40 crores by the end of this year.
    Show source
    Santosh Agarwal: INR 40 crores, we can assume.
  • Tarsons expects its entire 4-year CAPEX plan to generate around INR 400 crores of incremental revenue over and above what its existing facilities generate, with a fixed asset turnover of around 0.8 times.
    Show source
    So, we are looking at somewhere around INR 400 crores of incremental revenue over and above what we have in our facilities existing through the entire 4-year CAPEX plan.
  • Tarsons’ current interest run rate is about INR 20 crores per year, which it believes will continue in FY’27 and go down in FY’28.
    Show source
    Santosh Agarwal: Sir, our current run rate is about to be INR 20 crores per year.
Show 18 more statements

What management expects

  • Tarsons considers 20% to 22% growth doable, but says achieving it depends on how successfully it launches new products; it believes 15% growth is possible given overall market growth, with growth beyond 15% depending substantially on the success of new products.
    Show source
    Kiran: So, we are saying 15% growth is what we can possibly achieve given the overall market rate growth and we obviously grow faster than the market and then the delta beyond 15% depends a lot on the new products and the success of our new products.
  • Tarsons’ current view is that margins for the rest of the financial year will be similar to Q1, but a drastic positive or negative change in input costs over the approximately 7 to 7.5 months left could make a big difference to margins; input costs are currently a direct hit of about 4.5%, 5%, or almost 500 basis points on gross margin or material margin.
    Show source
    But if input costs, because see, it is a direct hit of about 4.5%, 5%, 500 basis points almost on the gross margin or the material margin.
  • Tarsons had revenue from its Panchla and Amta facilities in Q1 FY’27 and expects the ramp-up to continue over the quarters in FY’27 and strengthen in FY’28.
    Show source
    But we expect that ramp up to keep continuing in these quarters over FY’27 and keep getting stronger in FY’28 as well.
  • Tarsons ideally expects Panchla and Amta to contribute at least 20% to 25% of its standalone revenues in FY’28.
    Show source
    Aryan Sehgal: We would ideally expect Panchla and Amta to at least contribute to 20% to 25% of our standalone revenues in FY’28.
  • Tarsons does not expect annual maintenance CAPEX to exceed about INR 20-odd crores per year, although it could be INR 25 crores in some tough years.
    Show source
    But we don’t expect to exceed that or more than INR 20-odd crores per year.
  • Tarsons expects approximately INR 65 crores to INR 70 crores from its entire portfolio of new products in FY’28, which could include cell culture products.
    Show source
    Aryan Sehgal: Yes, so we could expect from my entire portfolio of new products, approximately INR 65 crores to INR 70 crores in the next year is what we expect from our entire new portfolio .
  • Tarsons expects white labeling to be a key growth driver in its export business going forward.
    Show source
    We are seeing encouraging opportunities in the white labeling segment and expect this to be a key growth driver in the export business going forward.
  • Tarsons plans to deepen its presence in India’s cell culture market over the next two to three years and pivot toward specialized biopharmaceutical products over the next two or three years to gain a meaningful share in that market; it also plans to ramp up its benchtop equipment business, which accounts for a very low volume of its business, with CAPEX that is not very large compared to plastics.
    Show source
    And once we are done with all this, I think our benchtop equipment space, which accounts for a very low volume of our business, we would look to ramp that up as well, which is not a very, very large CAPEX compared to plastics.
  • Tarsons expects strong year-over-year growth in all its India revenues, including export and domestic revenues; sales in Germany from its strategic buyout are expected to be less consistent, while launching more products and expanding its base in Germany is expected to drive significant growth in consolidated revenues.
    Show source
    Aryan Sehgal: See, what a fair reading of the situation would be that India, we are more aligned at this point in time with our standalone revenues and we could expect strong growth moving forward year- over-year for all our revenues in India, either export or domestic.
  • Nerbe has a strong network of distributors and direct sales teams in Germany and focuses on select niche products for German customers; Tarsons sees growth opportunities for Nerbe to expand geographically outside Germany, broaden its product portfolio beyond products it has sold, and undertake backward manufacturing for Tarsons.
    Show source
    So, there lies tremendous growth opportunities for Nerbe to expand their geographical presence outside Germany to similar levels to what there is in Germany, as well as expand their entire product portfolio from Tarsons offering to products beyond what they have sold and also a lot of backward manufacturing for Tarsons.
  • Tarsons expects to do much better with its roller bottles and bioprocess pharma containers in the coming quarters and years; management says the products are well accepted by customers, but becoming an alternate or secondary supplier and increasing volumes takes time.
    Show source
    Page 17 of 18 Tarsons Products Limited August 11, 2026 But to be able to get into customer SOPs and to be able to be an alternate, there is a process of being an alternate or a secondary supplier to the primary supplier who has been there for years or decades, and then move up the ladder and increase your volumes.
  • Tarsons expects its investments in incremental capacities, enhanced manufacturing capabilities and expanded product portfolio to contribute meaningfully over the coming years. Replaced by a later filing.
    Show source
    These investments are expected to contribute meaningfully over the coming years.
  • Tarsons expects operating leverage to support margin expansion as facility ramp-ups and revenue contributions scale progressively over the coming years. Replaced by a later filing.
    Show source
    We expect the operating leverage to support the margin expansion.
  • Tarsons expects underlying operating performance to strengthen as new facilities scale up, with improving capacity utilization and operating leverage supporting profitability. Replaced by a later filing.
    Show source
    Importantly, the underlying operating performance is expected to strengthen as new facilities scale up, with improving capacity utilization and operating leverage supporting profitability going forward.
  • Tarsons expects stronger revenue growth, improved operating leverage and corresponding improvement in profitability as it deepens its domestic and international presence and ramps up utilization of expanded capacities. Replaced by a later filing.
    Show source
    Going forward, as we deepen our presence across domestic and international markets, our ramp - up utilization of our expanded capacities, we expect stronger revenue growth, improved operating leverage and a corresponding improvement in profitability.
  • Tarsons expects costs to stabilize and its margin to improve as utilization ramps up over the coming years. Replaced by a later filing.
    Show source
    We expect this cost to stabilize and margin to improve as utilization ramps up over the coming years.
  • Tarsons’ focus in international markets is to grow its base and market share, with possible operational leverage to improve margins when the market is more stable. Replaced by a later filing.
    Show source
    But at this point in time, our entire focus is to be able to grow our base and market share in international markets.

Orders

  • Tarsons’ export customer inquiries and order pipelines recovered with healthy momentum, and increasing inquiries translated into order conversions. Replaced by a later filing.
    Show source
    Customer inquiries and order pipelines have recovered with healthy momentum, with increasing inquiry levels translating into healthy order conversions.

What it is building and selling

Projects and capacity

  • Tarsons had around INR 20 crores in capital advances and around INR 160 crores in CWIP on its balance sheet, and its major objective was to complete this pending CAPEX; only some maintenance CAPEX would also fall in place.
    Show source
    Currently, in our balance sheet, total capital advances lying is around INR 20 crores and CWIP is around INR 160 crores.
  • Tarsons expected the existing CAPEX, represented by its advances and CWIP, to be completed within Quarter 2 or Quarter 3; this was not new CAPEX.
    Show source
    It will be completed within Quarter 2 or Quarter 3 and this is not a new CAPEX.
  • Tarsons began a large-scale capacity expansion program around four years ago to strengthen manufacturing capabilities, expand its product portfolio and create a platform for long-term growth.
    Show source
    Around four years ago, Tarsons embarked on a large-scale capacity expansion program with a clear strategic objective to significantly strengthen our manufacturing capabilities, expand our product portfolio and create a stronger platform for long-term growth.
  • Tarsons expects the remaining facilities to be fully commissioned during Q2, with revenue contribution beginning from the second half.
    Show source
    We expect these facilities to be fully commissioned during Q2, with revenue contribution beginning from second half.
  • Tarsons undertook the largest-ever CAPEX program in the company, significantly expanding its capacities, capabilities and product portfolio.
    Show source
    During this period, we undertook the largest ever CAPEX program in the company, significantly expanding our capacities, capabilities and product portfolio, thereby creating a strong foundation for the next phase of growth.
  • Tarsons has no major CAPEX planned for this year, apart from maintenance and required CAPEX.
    Show source
    Otherwise, there will not be any major CAPEX.
Show 17 more statements

Projects and capacity

  • A large portion of the products at Tarsons’ Panchla facility have been commissioned, while a few select lines continued commissioning in Q1 FY’27; the number of machines and lines and supplier and engineering challenges delayed commissioning of the remaining lines by a few months. Replaced by a later filing.
    Show source
    It is just the sheer volume of the number of machines and the number of lines which is leading to a delay of a few months on the remaining lines to be commissioned.

Demand and pricing

  • Tarsons saw a meaningful demand revival and improvement across the end-to-end industries it serves, with a notable uptick in customer inquiries during Q1 FY’27.
    Show source
    We have seen a meaningful revival and improvement in the demand and momentum across end-to-end industries we serve, with a notable uptick in customer inquiries during this quarter.
  • Tarsons implemented partial price increases during Q1 FY’27 to mitigate higher input costs and expects the full benefits to flow through with a one-quarter lag.
    Show source
    To mitigate the impact of these higher input costs, we have implemented partial price increases during the quarter, with full benefits expected to flow through with a one-quarter lag.
  • Tarsons estimates that the government market accounts for about 15%, and at most 20%, of the INR 1,300 crores market.
    Show source
    So, on the INR 1,300 crores market, I believe the government market would account for about 15%, at best 20% of that market.
  • Tarsons said it can penetrate markets that global peers find difficult to serve or do not pay much attention to, while identifying war, conflicts, rising inflation costs and tariff threats as bigger problems than global competition.
    Show source
    We have a market which we can penetrate, which the global peers find it difficult or do not pay much attention to and I think the bigger factor for us to look at this point in time is the global environment with the war, the conflicts, the rising inflation costs, tariff threats looming, coming in and out.
  • Tarsons said it faces little direct Chinese competition in the business it currently conducts in India, while Chinese competition in Europe and the U.S. has not reduced; in India, Chinese competition was mainly in low-end segments where Tarsons did not compete and in cell culture.
    Show source
    We do face intense Chinese competition internationally from Chinese players in different parts of the world, in Europe and U.S. and that intensity has not reduced.
  • Tarsons believes the domestic market is almost back to the late single digits, its traditional pre-COVID growth level.
    Show source
    Aryan Sehgal: I believe we are almost there to the late single digits where the domestic market traditionally grew at pre-COVID levels.
  • Tarsons has taken certain price hikes in the domestic market, but they are small relative to the total cost impact.
    Show source
    Aryan Sehgal: We have taken certain price hikes, but it is a small size of the total cost impact in the domestic market only.
  • Tarsons says its share in government business has gone down; it says the GEM portal has significantly brought down business volumes in the international and domestic markets, especially because research institutes have abolished many of their former rate contracts and must now use a GEM bid for each procurement.
    Show source
    The GEM portal, although works well, and we do a lot of business to the GEM portal, but that has significantly brought down business volumes in the international market and in the domestic market, especially because of these research institutes where we had rate contracts in the past, a lot of these research institutes have abolished rate contracts.
  • Tarsons’ export growth is supported by participation in international trade fairs and exhibitions, which enhanced its visibility and enabled engagement with new customers and markets. Replaced by a later filing.
    Show source
    The growth in exports is also being supported by our ongoing participation in international trade fairs and exhibitions, which has further enhanced our visibility, enabled us to engage with new customers and markets.
  • Tarsons said it is positioned to produce high-quality products at reasonable prices as customers move toward better-priced alternatives that maintain the same quality levels. Replaced by a later filing.
    Show source
    But as the world is moving more towards a better -priced alternative with maintaining the same quality levels, I think the way our operations are positioned, we are a lean company being able to produce very respectably high -quality products at reasonable prices.
  • Tarsons said product quality followed closely by price is among the most important ways players differentiate themselves in the market. Replaced by a later filing.
    Show source
    Aryan Sehgal: No, I think it is product qualities seems to be one of the most important points followed closely by price.

Segments

  • Tarsons has people working out of India to look after territories outside the U.S. and Europe, and is in the process of establishing more direct local presence and adding distribution channels as revenues scale up; most business outside the U.S. and Europe is on a branded basis, not an OEM basis.
    Show source
    But we are in the process Page 6 of 18 Tarsons Products Limited August 11, 2026 of even having more direct local presence as our revenues scale up and adding more distribution channels because most of the business which happens outside U.S. and Europe happens on branded basis, not on an OEM basis.
  • Tarsons’ media bottles and roller bottles, launched last year, are fully commercialized and selling in the market.
    Show source
    And they are fully commercialized and selling in the market.
  • Tarsons’ manufacturing and R&D team has built a successful product in roller bottles and bioprocess pharma containers.
    Show source
    But the hard part of it to be able to build a world-class product in the roller bottles and the bioprocess pharma containers, that is our manufacturing and R&D team have done a wonderful job there and we have been able to build a very, very successful product there.
  • Tarsons said the ability to consistently deliver a large portfolio of products to customers over a considerable period differentiates companies in the market. Replaced by a later filing.
    Show source
    But I think the ability to deliver a large portfolio of products consistently to the customer over a considerable period of time is what differentiates various comp anies in the market.

Deals and partners

  • Tarsons sees an opportunity to cross-sell Tarsons-manufactured products through Nerbe’s established network and customer relationships.
    Show source
    Leveraging Nerbe’s established network and strong customer relationships to cross-sell Tarsons-manufactured products presents a meaningful opportunity for us.

Risks, rules and outside factors

Outside factors

  • Tarsons said it calibrates pricing to the competitive environment, where prices move up and down, companies with older inventories may sell at lower prices, and international companies are not seeking to increase prices very sharply; it said current gross-margin erosion is due to external factors rather than internal operating metrics.
    Show source
    So, regarding the bottom of our gross margin level, it is difficult to say because today what is happening is most of the margin erosion what is happening is happening because of an external environment factor, right?
  • Tarsons’ export shipments are nominated by buyers and are outside its control; vessel availability amid the West Asia crisis can cause a bad export quarter without indicating the business’s performance in that quarter.
    Show source
    So, we could have a bad quarter for exports in the next quarter or the quarter after that or any of the quarters in the future and that could mean nothing to our business performance in that quarter.
  • Tarsons says rumors of tariffs moving again on India and sharply increasing input costs in India are making the market environment challenging; it is maintaining prices and using the weaker rupee to improve realizations or partially offset higher input costs.
    Show source
    The environment and market is challenging, specifically because of rumors of tariffs moving again on India, as well as input costs drastically increasing in India.
  • Tarsons says logistics, transportation and input costs are the major hurdles to doing business, rather than tariffs.
    Show source
    At this point in time, logistics, transportation and input costs are the major hurdle, not so much the tariffs.

Everything else said on the call

What management stressed

  • Tarsons said it must be cautious about domestic and international industry conditions as it seeks to scale up revenue. Replaced by a later filing.
    Show source
    So, at this point in time, as we would like to scale up our revenues, we have to be very cautious about where the industry stands both domestically and internationally.

People and governance

  • Tarsons’ international sales team is currently based in India and looks after international markets; as the company scales up further, it would consider local hiring in certain key geographies.
    Show source
    Internationally, for now, the team will be based out of India, looking into international markets.
  • Tarsons has mid- to senior-level hires reporting to its senior sales hire.
    Show source
    So, we have a lot of mid to senior level hirings happening alongside but all below the gentleman.
  • Nerbe has not made many increases to its sales team because its business has been very stable over the last two or three years, but it has upgraded the team by changing people, bringing in more experienced industry people, and seeking to strengthen the team through quality rather than necessarily increasing headcount.
    Show source
    Aryan Sehgal: So, there have not been a lot of increases in the sales team, because Nerbe’s business has also been very, very stable over the last two or three years.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Rushabh Shah: So, my question was that in the last few years, we have always mentioned in our commentary that we need to focus more on exports, which will give us significant growth opportunities. So, I just wanted to know what would be our strategy to fight against the se global peers, since they have more stronger balance sheets and more number of S KUs as compared to Tarsons?

    Answer, aryan sehgal

    Aryan Sehgal: So, I think the business segments are quite different. Most of the larger global peers in the U .S. and in Europe are branded players with established markets, established distribution networks and established customer bases. But as the world is moving more towards a better -priced alternative with maintaining the same quality levels, I think the way our operations are positioned, we are a lean company being able to produce very respectably high -quality products at reasonable prices. We have a market which we can penetrate, which the global peers find it difficult or do not pay much attention to and I think the bigger factor for us to look at this point in time is the global environment with the war, the conflicts, the rising inflation costs, tariff threats looming, coming in and out. Every year, I think these are bigger problems than global competition. Global competition was always there pre -COVID era as well and will continue to be there even today and we are well-positioned to be able to find a spot and space for us in that market.

  2. Question

    Rushabh Shah: Second question was, how does each player differentiate itself in the market, like players like Tarsons, Abdos or Accumax? Can you give an idea between the industry, how does one player differentiate itself? Is it only the product quality and the price or something else also?

    Answer, aryan sehgal

    Aryan Sehgal: No, I think it is product qualities seems to be one of the most important points followed closely by price. But I think the ability to deliver a large portfolio of products consistently to the customer over a considerable period of time is what differentiates various comp anies in the market.

  3. Question

    Rushabh Shah: And my last question is, since we are looking to grow our business outside U .S. and Europe, although we have a majority of revenue coming from there but have we added any of marketing people in those countries where we need to get validation from our customers, like outside U .S. and Europe? Have we taken any steps to increase our business out there?

    Answer, aryan sehgal

    Aryan Sehgal: We have taken steps. We do not have people directly positioned in those countries as of now. We have people working out of India, looking after those territories. But we are in the process Page 6 of 18 Tarsons Products Limited August 11, 2026 of even having more direct local presence as our revenues scale up and adding more distribution channels because most of the business which happens outside U.S. and Europe happens on branded basis, not on an OEM basis.

  4. Question

    Jasdeep Walia: Sir, why has Panchla commercial commissioning has been delayed? Now, in the beginning of FY’26, you had guided for full commissioning at the commercial level by the start of FY’27. Now, it’s gotten shifted to second half of FY’27. So, what are the reasons which are driving this delay?

    Answer, aryan sehgal

    Aryan Sehgal: It is just the sheer scale and size and the number of projects coming in at Panchla. So, as I mentioned in my opening remarks that a large portion of the products have been commissioned, but there are still a few select lines which continue being commissioned in this quarter. So, we are dependent on a lot of external factors, a lot of engineering teams from across the world which are finalizing on the machines once they have entered into our facilities. So, there are a lot of variables involved in this. And different suppliers come up with different kinds of challenges and different operational issues which you have to resolve for, which is a very standard and normal part. It is just the sheer volume of the number of machines and the number of lines which is leading to a delay of a few months on the remaining lines to be commissioned.

  5. Question

    Jasdeep Walia: And sir, what has been the contribution of Panchla to revenues in this quarter?

    Answer, aryan sehgal

    Aryan Sehgal: So, we don’t have an exact number in line, but most of the revenue contributed from Panchla in Quarter 1 are for existing products or capacity expansions which have moved into Panchla. Jasdeep Walia: So, first quarter doesn’t have contribution from cell culture products?

    Answer, aryan sehgal

    Aryan Sehgal: No, not from the cell culture consumables, but it has got contribution from the bioprocess containers and so on, which are the media bottles and roller bottles.

  6. Question

    Jasdeep Walia: Those were launched last year, right?

    Answer, aryan sehgal

    Aryan Sehgal: Yes, absolutely. And they are fully commercialized and selling in the market.

  7. Question

    Jasdeep Walia: And in the recent past, have you seen any reduction in competition from Chinese companies, given the fact that Chinese government has withdrawn significant amount of export incentives in the current year?

    Answer, aryan sehgal

    Aryan Sehgal: See, in India, most of the competition from Chinese companies came in segments we could not ever compete in or which we did not have a market line for, which is a very, very low-end Page 7 of 18 Tarsons Products Limited August 11, 2026 segment and in the cell culture segment, because that was dominated mainly by MNCs and some Chinese players had a small share. So, what we do directly today as a business in India, we don ’t have much direct Chinese competition. We do face intense Chinese competition internationally from Chinese players in different parts of the world, in Europe and U.S. and that intensity has not reduced.

  8. Question

    Jasdeep Walia: And, sir, what is the gross and net debt as of now and interest expense and depreciation expense, have they peaked in this quarter and we will see a reduction going forward or what could be the trend?

    Answer, santosh agarwal

    Santosh Agarwal: This is Santosh here. So, I am giving the answer for this. The gross debt for the company is about to be INR 380 crores, and the net debt is about to be INR 330-340 crores, something like that. And regarding your question on depreciation, this year our depreciation on standalone basis is INR 24.5 crores. That includes a depreciation of INR 14 crores from Panchla and INR 4 crores from Amta and still we have INR 160 crores of capital work in progress, which we think that, that will be capitalized and moved to main capital asset segment in the subsequent quarter. So, we believe that in the full year, the depreciation will be in the range of approximately INR 105 crores to INR 110 crores. That would be the peak year for our depreciation.

  9. Question

    Jasdeep Walia: And sir, what is the debt reduction target for this year?

    Answer, santosh agarwal

    Santosh Agarwal: Debt reduction target is about to be, we are paying approx INR 70 crores of loan repayment, and some LCs are also there, which gets converted into term loans. So, effectively, we believe that INR 40 crores to INR 50 crores rupees of debt should be reduced year-on-year basis.

  10. Question

    Jasdeep Walia: So, net debt will reduce by INR 40 crores to 50 crores by the end of this year?

    Answer, santosh agarwal

    Santosh Agarwal: INR 40 crores, we can assume.

Show 13 more questions
  1. Question

    Jasdeep Walia: And sir, what are the CAPEX plans for this year?

    Answer, santosh agarwal

    Santosh Agarwal: There is no CAPEX plan as such. As we already said that some maintenance CAPEX and some required CAPEX will only be undertaken. Otherwise, there will not be any major CAPEX. Jasdeep Walia: That is all from my side.

    Answer, aryan sehgal

    Aryan Sehgal: The thing is, as I mentioned in one of my remarks, we have to calibrate pricing based on the competitive environment. What is happening is, prices are moving up and prices are moving down. There are a lot of inventories which are there in the system. Some companies that have older inventories could sell at lower pricing and so on. So, a lot of international companies also not wanting to increase prices very, very sharply. So, regarding the bottom of our gross margin level, it is difficult to say because today what is happening is most of the margin erosion what is happening is happening because of an external environment factor, right? It is nothing related to our internal operation metrics within the company.

    Answer, aryan sehgal

    The pure reason for gross margin going down is higher input costs and higher purchase price of raw materials and inability to pass on the entire price increase to customers. So, at this point in time, as we would like to scale up our revenues, we have to be very cautious about where the industry stands both domestically and internationally. Aditya: And sir, how do you see the domestic market going forward in terms of demand? So, we are coming out of a low base where there was a huge de-stocking and there was some competitive pressure. But now going forward, how do you see the domestic market evolving for us both in terms of demand and competitive intensity? Page 9 of 18 Tarsons Products Limited August 11, 2026 Aryan Sehgal: So, we look at the domestic market in a multitude of ways.

    Answer, aryan sehgal

    One is we have a very strong base , and we look to leverage strongly into this base and increase our market share and wallet share with customers for our existing products. We look to get very deep into the cell culture market over the next two to three years and hold a meaningful share in India in the cell culture space. And you must have seen in the government budgets in February this year that the government is focusing very strongly on the biopharma with the biopharma Shakti scheme and so on and putting a lot of emphasis on biopharma. So, what we do today, we cater a lot of our products to the pharmaceutical and the biopharmaceutical needs. And we would also look at a strong pivot into specialized biopharmaceutical products over the next two or three years to be able to gain a meaningfu l share in that market as well. And once we are done with all this, I think our benchtop equipment space, which accounts for a very low volume of our business, we would look to ramp that up as well, which is not a very, very large CAPEX compared to plastics. But with our distribution network and our strength across the country, we should be able to leverage and gain a lot on the lab equipment and the benchtop space.

    Answer, aryan sehgal

    So, that is how we look to counter these four reasons , which I believe we would be able to have a very robust growth in the domestic market and be able to strengthen our market share further. Aditya: Just one follow up. So, I believe the domestic market used to grow at around 8 % to 9%. So, are we back to that growth phase?

    Answer, aryan sehgal

    Aryan Sehgal: I believe we are almost there to the late single digits where the domestic market traditionally grew at pre-COVID levels. Aditya: Sir, now coming to exports… Moderator: Sorry to interrupt, Aditya, may we please request you to rejoin the queue for the follow-up questions?

  2. Question

    Rahul Jain: Sir, first question is with regard to the CAPEX. So, till date, how much CAPEX has been completed and further, what is the amount of CAPEX which is to be done to complete our entire CAPEX, the huge CAPEX plans?

    Answer, santosh agarwal

    Santosh Agarwal: So, I will give you a perspective. Currently, in our balance sheet, total capital advances lying is around INR 20 crores and CWIP is around INR 160 crores. So, our major objective is to complete this whole pending CAPEX. Apart from that, some maintenance CAPEX will only fall in place. Page 10 of 18 Tarsons Products Limited August 11, 2026 Rahul Jain: No. So, typically, the amount of CAPEX from the large CAPEX which is pending, is it further INR 150-160 crores that gets completed by the end of Quarter 2?

    Answer, santosh agarwal

    Santosh Agarwal: Not by quarter 2. It will be completed within Quarter 2 or Quarter 3 and this is not a new CAPEX. This is the advance related to and CWIP related to the existing CAPEX. Rahul Jain: And sir, with regards to once this CAPEX is completed, say by Quarter 3 and whatever we have done till date. So, firstly, whatever we have done till date, what kind of sales is possible at peak utilization for the CAPEX which gets completed by Quarter 3, including the one which is done till date?

    Answer, aryan sehgal

    Aryan Sehgal: So, on a fixed asset basis, we should be able to turn in at around 0.8times. So, we are looking at somewhere around INR 400 crores of incremental revenue over and above what we have in our facilities existing through the entire 4-year CAPEX plan.

  3. Question

    Rahul Jain: And with regards to one previous participant asked a question about interest. So, the interest run rate which is roughly about INR 25 crores for the year, including the CAPEX which is supposed to get completed in next 2 quarters, can we say this INR 25 crores is the peak interest cost on a yearly basis?

    Answer, santosh agarwal

    Santosh Agarwal: Sir, our current run rate is about to be INR 20 crores per year. And we believe that the same rate will continue in FY’27 also. But in FY’28, it will go down.

  4. Question

    Rahul Jain: It will go down. Sure. Last question, sir. In terms of this entire CAPEX, how do you see the ramp up in FY’27, FY’28 and FY’29?

    Answer, aryan sehgal

    Aryan Sehgal: So, I believe that the industry position looks much stronger than, you know, it looks the strongest ever in the last 4 to 5 years, is what I believe and if you see our numbers pre-2021, which is pre- COVID, we have grown at a sustainable level of 15% and above every year. So, moving forward, I believe that our growth level should be at least that or more because now we have larger facilities, a stronger company, much larger product line and a lot of new products to offer as well.

  5. Question

    Can you highlight some key hirings that you have done and their profile?

    Answer, aryan sehgal

    Aryan Sehgal: So, the key hiring, what we have done for sales in a senior level position in an SMB position that was already communicated to the markets and he would be involved in a lot of revenue and strategy and growth for the company and a lot of teams are being built below him domestically, as well as in certain key geographies. Internationally, for now, the team will be based out of India, looking into international markets. But as we scale up further, we would look at some local hiring in certain key geographies.

  6. Question

    Jasdeep Walia: Sir, except the hiring that you have disclosed to the exchanges, any other senior level hire that you have done?

    Answer, aryan sehgal

    Aryan Sehgal: No, otherwise we would have disclosed it. We would have been an SMP. So, we have a lot of mid to senior level hirings happening alongside but all below the gentleman. So, all reporting to the gentleman.

  7. Question

    Jasdeep Walia: That is all from my side.

    Answer, aryan sehgal

    Aryan Sehgal: See, what a fair reading of the situation would be that India, we are more aligned at this point in time with our standalone revenues and we could expect strong growth moving forward year- over-year for all our revenues in India, either export or domestic. The sales in Germany, as we said earlier, it is more of a strategic buyout for us and it would not be as consistent. There would be larger years where the growth would grow beyond those numbers but it would not be more, it would not be as consistent as the same levels of consistent growth year-over-year. Because as we launch more products and expand our base in Germany, we would see some strong significant growth coming from our consolidated revenues as well. Kiran: That is the first question. Second question, sir, is what will it take for us to grow beyond the 15% growth number? Is it the success of the cell culture line?

    Answer, aryan sehgal

    Aryan Sehgal: Yes, I think cell culture is a very sensitive line of products with a lot of established players and hence we are trying to find a strong space for us in that market. We have the product, we have the quality and now we will try and leverage our network and our marketing and sales to be able to deliver that and I believe that we are more concerned about growth, which is sustainable. We would like to grow very, very aggressively, but not over aggressively because sometimes growth, which beyond a certain point, sometimes it is not very, very sustainable as well. So, while 20%, 22% looks doable and very strong growth number, there will be a lot of factors involved with how successfully our new products can be launched for these numbers. Kiran: So, we are saying 15% growth is what we can possibly achieve given the overall market rate growth and we obviously grow faster than the market and then the delta beyond 15% depends a lot on the new products and the success of our new products.

    Answer, aryan sehgal

    Aryan Sehgal: For now, it looks like we could with our Quarter 1 having exceeded 15% growth, and it looks like the demand is recovering well, and we are growing strongly. Nishitha: And on the margin front, like, because of the input cost, you mentioned that our margins have taken a hit. So, how do you see the margin behaving for the full year FY’27? What can we see the exit EBITDA margin in FY’27?

    Answer, aryan sehgal

    Aryan Sehgal: For now, it looks similar to what we have achieved in Q1. But if input costs, because see, it is a direct hit of about 4.5%, 5%, 500 basis points almost on the gross margin or the material margin. So, again, we still have 7 months, approximately 7, 7.5 months left for this entire financial year. Page 13 of 18 Tarsons Products Limited August 11, 2026 So, the external environment is very, very volatile and for now, if you ask me, it looks similar to what we have done in Q1. But if these input costs change drastically, positively or negatively in the seven months, it could make a big difference to our margins. Nishitha: And from the new facility, the Panchla facility and the Amta facility, when can we expect the facilities to contribute to the revenue from FY’28? Or can we expect some revenue to come in FY’27 as well?

    Answer, aryan sehgal

    Aryan Sehgal: Revenues are coming even today. In Q1 revenue, also, we have revenue coming in from Panchla and Amta. But we expect that ramp up to keep continuing in these quarters over FY’27 and keep getting stronger in FY’28 as well. Nishitha: So, what sort of revenue can we expect from these two facilities in FY’28? What sort of growth can we expect from these two facilities?

    Answer, aryan sehgal

    Aryan Sehgal: We would ideally expect Panchla and Amta to at least contribute to 20% to 25% of our standalone revenues in FY’28. Nishitha: That is it from me.

  8. Question

    Bhavya Doshi: So, just wanted to understand what kind of turnover we are expecting from the cell culture products for FY’28 and also, if you can quantify the annual maintenance CAPEX for this year and FY’28 as well.

    Answer, aryan sehgal

    Aryan Sehgal: So, for now in this year, in the first 4, 4.5 months, we have had very limited annual maintenance CAPEX and moving forward, the problem is we can’t really budget an annual maintenance CAPEX because that is always on existing lines, machine breakdowns, some mold repairs, mold maintenance, adding newer molds for molds which have run its life and so on. But we don’t expect to exceed that or more than INR 20-odd crores per year. Maybe in some tough years, it could be INR 25 crores.

  9. Question

    Bhavya Doshi: And so the revenue that we might be expecting from the cell culture products for next year, ‘28?

    Answer, aryan sehgal

    Aryan Sehgal: Yes, so we could expect from my entire portfolio of new products, approximately INR 65 crores to INR 70 crores in the next year is what we expect from our entire new portfolio . That could include cell culture as well.

  10. Question

    Bhavya Doshi: And sir, for this year, are we planning to take any price hike across our product portfolio, some percentage in order to tackle the RM cost?

    Answer, aryan sehgal

    Aryan Sehgal: We have taken certain price hikes, but it is a small size of the total cost impact in the domestic market only. Page 14 of 18 Tarsons Products Limited August 11, 2026 Bhavya Doshi: Can you quantify like what percentage would be?

  11. Question

    Nikhil Upadhyay: I have two questions on the export side. See, if I look at, read your commentary in last quarter on exports, there were many challenges which we had seen and even for full of FY’26. So, this quarter, what growth which we have seen, is there some benefit of some shipments also or is it a normal sale which you are looking at even on a sequential basis?

    Answer, aryan sehgal

    Aryan Sehgal: No, there is a huge benefit of shipments as well because what happens is shipments are beyond our control. When we define the revenue for a quarter, we need to close shipments on a particular date before the quarter ends. And many of our shipments are nominated by our buyers and not in our control. So, with the West Asia crisis, availability of vessels and ships is also not at the best situation. So, we could have a bad quarter for exports in the next quarter or the quarter after that or any of the quarters in the future and that could mean nothing to our business performance in that quarter.

  12. Question

    Nikhil Upadhyay: And second question was on Nerbe. You mentioned that in your initial call, you mentioned now we would be looking at more integration of products between India and Nerbe. Can you just talk about what is the total size of market and what percentage of market Nerbe was existingly meeting the demand and based on our manufacturing facilities today, we can completely track the whole market segment and is Nerbe only strong in Germany, or do they have a good enough presence in whole of Europe?

    Answer, aryan sehgal

    Aryan Sehgal: So, Nerbe is a very similar company to Tarsons. If you take Tarsons as 65% of business in India and 35% of business outside India, let us consider Germany as the domestic market and outside Page 15 of 18 Tarsons Products Limited August 11, 2026 Germany as an international market, Nerbe would probably be 70% in Germany and 30% outside Germany. And out of that 30%, 95% would be in EU. So, they would do very little sales outside the European Union. So, the majority business comes out of Germany. They have a very strong network of distributors and direct sales teams in Germany and they are a very focused supplier on select niche products in the German market to German customers. So, there lies tremendous growth opportunities for Nerbe to expand their geographical presence outside Germany to similar levels to what there is in Germany, as well as expand their entire product portfolio from Tarsons offering to products beyond what they have sold and also a lot of backward manufacturing for Tarsons.

    Answer, aryan sehgal

    Aryan Sehgal: So, there have not been a lot of increases in the sales team, because Nerbe’s business has also been very, very stable over the last two or three years. But of course, there have been a lot of upgrades in the sales team. They have changed a lot of people and brought in more experienced people from the industry and they are looking at ways to strengthen the team. That strength is coming more from the quality of the people, not necessarily from the number of people.

  13. Question

    Nikhil Upadhyay: I will come back in the queue.

    Answer, aryan sehgal

    Aryan Sehgal: It is challenging. The environment and market is challenging, specifically because of rumors of tariffs moving again on India, as well as input costs drastically increasing in India. But we are finding ways of countering that by maintaining prices and using the advantage of the weaker rupee for better realizations or to maintain the costs which are offset with the high input costs, partial offsets. Page 16 of 18 Tarsons Products Limited August 11, 2026 But we are as flexible and as aggressive as possible in international markets. Our own endeavor at this point is to increase and build our base internationally and then, at a more opportune time when the market is more stable, we could find ways on how we can operationally leverage ourselves to improve our margins. But at this point in time, our entire focus is to be able to grow our base and market share in international markets. Aditya: And sir, now with tariffs now coming to 10%, have you seen more inquiries and an increase in order book, particularly from the U.S.?

    Answer, aryan sehgal

    Aryan Sehgal: Yes, the number of inquiries are there and the business looks very, very promising and strong as long as the environment remains conducive to do business . At this point in time, logistics, transportation and input costs are the major hurdle, not so much the tariffs. Aditya: And now, sir, in the domestic market of INR 1,200 crores to INR 1,300 crores, how much of that demand is generated from government institutions? And secondly, if you could help us understand the impact of GEM marketplace on our business. So, have you seen our share in government business going down in the last five to seven years?

    Answer, aryan sehgal

    Aryan Sehgal: Yes, I think our share in government business has gone down. The GEM portal, although works well, and we do a lot of business to the GEM portal, but that has significantly brought down business volumes in the international market and in the domestic market, especially because of these research institutes where we had rate contracts in the past, a lot of these research institutes have abolished rate contracts. And now they must move to a GEM bid every time they want to procure materials. So, on the INR 1,300 crores market, I believe the government market would account for about 15%, at best 20% of that market. Aditya: And any government grants or incentives which we are expected to receive for the CAPEX we have incurred in Panchla and Amta?

    Answer, aryan sehgal

    Aryan Sehgal: No, I think it is a sensitive product line. While we have done well, we expect to do much better in the coming quarters, in the coming years. The good part is that the product what we made is a very robust product, highly reliable and very well accepted by customers. Page 17 of 18 Tarsons Products Limited August 11, 2026 But to be able to get into customer SOPs and to be able to be an alternate, there is a process of being an alternate or a secondary supplier to the primary supplier who has been there for years or decades, and then move up the ladder and increase your volumes. That is a time-taking process. But the hard part of it to be able to build a world-class product in the roller bottles and the bioprocess pharma containers, that is our manufacturing and R&D team have done a wonderful job there and we have been able to build a very, very successful product there. Aditya: But do you think a similar time to scale up would be required in cell culture products or do you think the scale of cell culture can be minimized?

Questions about this call

When was the Tarsons Products Q1 FY27 earnings call transcript filed?
Tarsons Products filed the transcript with the exchange on 17 Aug 2026. This page is built from that transcript.
What does this page list?
78 statements from the transcript across 11 topics, 39 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 23 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Tarsons Products Q1 FY27 concall: what the company said · DalalOS